XCUR
Exicure, Inc. Common Stock
stockNASDAQ
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.24 | 2026-09-28 | -6.88% | -1.073 |
| 1M | 1.25 | 2026-09-04 | -8.00% | 0.689 |
| 3M | 1.99 | 2026-07-06 | -42.21% | 0.229 |
| 6M | 4.02 | 2026-04-06 | -71.39% | 0.887 |
| 1Y | 4.17 | 2025-10-03 | -72.42% | 0.517 |
| 2Y | 2.70 | 2024-10-04 | -57.41% | — |
| 5Y | 187.50 | 2021-10-04 | -99.39% | 0.774 |
Exicure, Inc. Common Stock (NASDAQ:XCUR) stock price today is $1.15, and today's volume is 5,310. XCUR is down 2.542% today. The 30 day average volume is 34,617. XCUR market cap is $7.53M with 6.55M shares outstanding.